Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for PVP-I  COVID-19 treatment studies for Povidone-Iod..  C19 studies: Povidone-Iod..  Povidone-Iod..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Povidone iodine gargle and mouthwash
Hassandarvish et al., British Dental Journal volume, doi:10.1038/s41415-020-1794-1 (In Vitro)
Hassandarvish et al., Povidone iodine gargle and mouthwash, British Dental Journal volume, doi:10.1038/s41415-020-1794-1 (In Vitro)
Jun 2020   Source   PDF  
  All Studies   Meta
In Vitro study showing undiluted PVP-I (1% w/v) achieved >5 log10 reduction in SARS-CoV-2 virus titres at 15, 30 and 60 seconds treatment exposure under both clean and dirty conditions. In contrast, when PVP-I was tested at 1:2 dilution a >4 log10 kill at 15 seconds and >5 log10 kill at 30 and 60 seconds in comparison to control was seen in both clean and dirty conditions.
8 In Vitro studies support the efficacy of povidone-iodine [Anderson, Bidra, Frank, Hassandarvish, Meister, Pelletier, Tucker, Xu].
Hassandarvish et al., 26 Jun 2020, peer-reviewed, 8 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperPovidone-Iod..All
Abstract: UPFRONT COMMENT Letters to the editor Send your letters to the Editor, British Dental Journal, 64 Wimpole Street, London, W1G 8YS. Email Priority will be given to letters less than 500 words long. Authors must sign the letter, which may be edited for reasons of space. CORONAVIRUS Special care and new environments Sir, patients with autism and other special care needs often rely on familiar surroundings, processes and faces when attending the dentist to reduce the sensory burden and anxiety of being in the dental environment. Any change to the ‘routine’ of attending may present such patients with difficulties that the dental team should have awareness of and be sensitive to. We must make every effort to prepare patients for the changes to the dental environment that they are used to attending such as the increased use of PPE. Sending photographs and advice of how layouts and processes may have changed within the practice and what to expect regarding PPE and infection control procedures ahead of their appointment to patients and carers could prove invaluable in maintaining both attendance for this potentially higher risk group, as well as talking through any new steps during their visit or procedure to maximise compliance. Technology can also be utilised to facilitate this, such as 360 degree photographs or video tours on practice websites or social media. Although aerosol generating procedures would ideally be carried out in a single visit, this may not be possible or practicable for this patient group. Any additional barriers to attending for regular preventive dental care could have significant longer term risks to the dental health of this already vulnerable patient cohort. A decrease in regular professional preventive input risks increasing the need for invasive procedures and sedation or general anaesthesia, in turn increasing risks to both dental and general health. We must therefore do everything we can to minimise the impact of these changes for patients with special care needs. S. Carr, South Tyneside, UK Povidone iodine gargle and mouthwash Sir, a recent letter in your journal by Challacombe et al. highlighted the potential of povidone iodine (PVP-I) mouthwash and nasal spray in reducing the risk of cross-infection of COVID-19 among the dentists and their assistants.1 The evidence used was based on in vitro data of PVP-I’s virucidal activity against coronaviruses such as SARS-CoV and MERS-CoV. Here, we demonstrate in vitro virucidal activity of an oral PVP-I product against SARS-CoV-2, the virus causing COVID-19. BETADINE Gargle and Mouth Wash in two concentrations, undiluted (PVP-I 1% w/v) and at a 1:2 dilution (PVP-I 0.5% w/v) was tested for virucidal activity (≥4 log10 reduction in viral titres) against SARS-CoV-2 in both clean (0.3 g/l BSA) and dirty (3.0 g/l BSA + 3 mL/L human erythrocytes) conditions at time points of 15, 30 and 60 seconds in a BSL-3 laboratory of the Tropical Infectious Diseases Research and Education Center (TIDREC), University of Malaya, Malaysia. The SARS-CoV-2 was isolated and propagated in Vero-E6 cells in TIDREC. The cytotoxicity of the product to the Vero-E6 cells was evaluated and taken into account when performing the kill time assay. Virus kill time assay was performed based on the established EN14476 methodology.2 Virus titres were calculated as 50% tissue culture infectious dose (TCID50/mL) using the Spearman-Karber method.2 The..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop